Boutique whole-body screening services use MRI to look for cancer and structural disease without radiation. Across 18,043 healthy adults (Ahsan JGIM 2026; Martins da Fonseca Eur Radiol 2026; Kwee 2019), scanning 1,000 asymptomatic people flags ~780 with an abnormality, ~320 with a critical or indeterminate finding, and ~150 with an actionable non-malignant finding (triggering ~86 follow-up workups and ~31 procedures) while finding cancer in ~14 to 16 people (1.4% to 1.57%) with zero randomized mortality proof (Cochrane 2026). We do not sell these scans; we help you decide whether one fits your hereditary/familial risk before you spend the money, and we apply ACR White Paper rules and non-invasive tie-breakers (CEUS, Eovist, chemical-shift MRI) so benign cysts never trigger needless biopsies.
TL;DR: Scanning 1,000 healthy adults with a commercial whole-body MRI flags about 780 people with an abnormality and 320 with an unclear spot, while finding true cancer in 14 to 16 people (about 1.5%).
- Match the scan to your personal risk: Whole-body MRI has no trial proof that it lowers deaths in average-risk adults, whereas cancer guidelines endorse yearly scans for high-risk gene carriers like Li-Fraumeni (where cancer yield is 7%).
- Check the 4 instant all-clear rules first: Once we confirm you have no prior cancer, immune suppression, or liver disease, four common findings need zero follow-up and zero biopsy: (1) non-cystic lung nodules under 6 mm in a low-risk adult, (2) simple liver cysts, hemangiomas, focal nodular hyperplasia, or smooth spots under 1 cm, (3) Bosniak I and II kidney cysts, and (4) CT or MRI thyroid spots under 1.0 cm (under age 35) or under 1.5 cm (age 35 and up).
- Use non-invasive tie-breaker scans before any needle: When a 1 to 2 cm spot looks unclear, contrast ultrasound (CEUS), gadoxetate liver MRI, or chemical-shift adrenal MRI settles 90% to 95% of cases without a biopsy.
A 45-year-old founder in Grad Hospital forwarded me his $2,499 commercial whole-body scan report at 4:45 PM on a Friday because it flagged four separate findings: a 4 mm right lower lobe lung nodule, a 1.1 cm liver hemangioma, a 1.8 cm thin-walled kidney cyst, and a 9 mm thyroid cyst. The report listed four specialist referral recommendations. After confirming he had no prior cancer, liver disease, or smoking risk, we pulled his images onto my screen and walked through the radiology society rules one organ at a time. His 4 mm lung nodule carried the same risk as having no nodule at all, his liver hemangioma and Bosniak I kidney cyst needed zero follow-up at any size, and his 9 mm thyroid cyst needed no biopsy. In thirty minutes, four scary specialist referrals became zero biopsies and a quiet weekend with his family.
Why has the full-body MRI grown so fast, and who benefits most?
Faster magnets and AI reconstruction let clinics image head to pelvis in 60 minutes without radiation. That is valuable for high-risk gene carriers (Li-Fraumeni TP53, Lynch, BRCA1/2) and complex family trees, while in average-risk adults the same sensitivity flags benign quirks in 78% to 95% of people (Zugni 2020; Ahsan 2026).
A mouthwash invented a disease is the clearest history of how commercial demand is built, and it is worth reading before buying any scan on your own. For patients with genetic risks or a strong family history of cancer, whole-body diffusion MRI can be a thoughtful part of a precision prevention plan when your physician applies strict follow-up rules so benign cysts do not lead to unnecessary procedures.
What are the boutique imaging options compared?
Boutique imaging options compared head-to-head:
| Service | Primary Claim | Pros | Cons |
|---|---|---|---|
| Full-Body MRI (MRI-DWI) | Early cancer and aneurysm detection. | No radiation, high tissue detail. | High cost ($1,500 to $2,500), high incidental finding rate. |
| Liquid Biopsy (Galleri) | Multi-cancer early detection via blood. | Simple draw, high specificity. | May miss very early small tumors. |
| PET-CT Scans | Metabolic activity of cancer cells. | Finds active growing tumors. | High radiation, not used for screening healthy adults. |
| Body Composition (DEXA) | Fat vs. muscle mass. | Gold standard for metabolic health. | Low cost, high clinical value. |
| Cleerly CCTA | Coronary plaque phenotyping. | Quantifies soft and calcified plaque. | Targeted to heart only, uses radiation. |
What is the "incidentaloma" problem?
Across pooled reviews of over 18,000 healthy adults (Kwee & Kwee 2019, Ahsan et al. 2026, Martins da Fonseca et al. 2026), scanning 1,000 healthy adults flags about 780 with an abnormal finding, 320 with a serious or unclear finding, and 150 with a non-cancer finding (leading to 86 follow-up scans or labs and 31 procedures), while true cancer is found in 14 to 16 scans (1.4% to 1.57%).

The incidentaloma cascade is the biggest risk of broad scans in average-risk adults. As a 2026 Cochrane review and a JAMA editorial by Davenport and Reeder point out, no randomized trial has shown that whole-body MRI screening cuts deaths or illness in the general public. By contrast, NCCN 2026 guidelines recommend yearly whole-body MRI for hereditary syndromes like Li-Fraumeni (TP53), where cancer yield is about 7% (versus 1.5% in the general public).
Four cohort findings show why unguided scans trigger so much follow-up testing:
- Unclear ONCO-RADS spots and false alarms: In Kwee and Kwee's review of 5,373 adults, 32.1% of screened adults had a serious or unclear finding and 16.0% of verified findings were false positives. In a 2026 ONCO-RADS study by Ali and colleagues, 42.2% had an ONCO-RADS 3 or higher spot (nearly all unclear Category 3) while true cancer was 0.9%.
- The 21,651-person pancreatic cyst cascade: In the largest screening MRI study to date (Wong et al., JAMA Network Open 2026), 7.0% of healthy adults had incidental pancreatic cysts (rising to 20.8% at age 80 and up). Only 0.08% had cysts larger than 3 cm, yet about 1,500 healthy people entered years of scan follow-up.
- Higher outpatient costs and benign biopsies: In Germany's SHIP study, sharing whole-body MRI findings raised 2-year outpatient costs by 11.6% (Schmidt BMJ Open 2022) and raised benign biopsies by 39% (rate ratio 1.39, Richter Eur J Epidemiol 2020).
- False reassurance: A normal whole-body MRI does not rule out common cancers. In a 576-person screening study by Basar and colleagues, 2.8% had false-negative scans, including missed colon, breast, and thyroid cancers.
How do ACR White Paper rules, ACG 2024 guidelines, and non-invasive scans stop needless biopsies?
When a boutique Prenuvo or Ezra report arrives in your inbox with 3 or 4 flagged spots, we first check that you have no known cancer, immune suppression, chronic liver disease, or warning symptoms (and that a chest CT was not ordered for smoker lung-cancer screening, which uses Lung-RADS). Next, we apply two layers of evidence before anyone touches a biopsy needle:
- Whole-scan ONCO-RADS scoring (Petralia et al., Radiology 2021): ONCO-RADS grades findings from 1 (normal) to 5 (highly likely cancer). In 2,064 screened adults (Hu et al. 2024), cancer was confirmed in only 0.1% of Category 2 scans and 5.4% of Category 3 scans, versus 42.9% of Category 4 and 75.0% of Category 5 scans.
- Organ-specific Fleischner 2017, ACG 2024, Bosniak v2019, and ACR TI-RADS cutoffs:
- Lung nodules (2017 Fleischner Society and SUMMIT Study, Creamer Thorax 2025): About 95% of incidental lung nodules in healthy adults aged 35 and up are benign old scars or lymph nodes. A single or multiple dense (non-cystic) nodule under 6 mm (under 100 mm3) in a low-risk adult carries under 1% cancer risk (0.5% in NLST) and the same cancer risk as having no nodule at all (0.88% vs. 0.77% in SUMMIT, n = 11,355). That means zero routine follow-up CT (in high-risk patients, an optional 12-month CT is used only if the spot is upper-lobe or spiky). Dense nodules measuring 6 to 8 mm (1% to 2% risk) get a CT at 6 to 12 months (any nodule stable for 2 full years is benign). Pure ground-glass nodules under 6 mm need no follow-up, and nodules over 8 mm (over 250 mm3) get a 3-month CT, PET/CT, or lung specialist review.
- Liver (ACG 2024 Guideline, Frenette et al. and ACR 2017 Gore et al.): In low-risk adults without cirrhosis or known cancer, over 95% of liver spots are benign. Under ACG 2024 rules, simple cysts (any size), hemangiomas (any size, birth control pills can continue, and biopsy is avoided), confirmed focal nodular hyperplasia (FNH, zero cancer risk, pregnancy safe), and smooth spots under 1.0 cm need zero follow-up. By contrast, liver adenomas require stopping estrogen pills and weight loss (women with adenomas under 5 cm get MRI every 6 months for 2 years then yearly; surgery if 5 cm or larger or at any size in men). For unclear spots 1.0 cm or larger, multiphasic MRI with gadoxetate (Eovist) solves up to 95% without a needle (94% to 97% of FNH glow bright on the liver phase with 93.9% sensitivity and 95.3% specificity, Suh 2015, noting some inflammatory adenomas also glow, Furumaya 2024). Contrast-enhanced ultrasound (CEUS) reaches 97.8% sensitivity for benign liver spots.
- Kidney (Bosniak v2019, Silverman 2019, McGrath 2025 and AUA 2021): Simple kidney cysts show up in over half of adults past 70. Plain ultrasound reliably calls Bosniak I (smooth wall 2 mm or thinner) and Bosniak II (1 to 3 thin dividing walls, any calcium, or a dense spot 70 HU or higher on non-contrast CT, which has a 99.9%+ chance of being a benign dense cyst). Both Bosniak I and II need zero follow-up (cyst growth alone is not cancer). Bosniak IIF (3 mm wall or 4+ thin walls) gets imaging at 6 months, 12 months, then yearly to 5 years (0 of 246 upgraded at 6 months in Shen 2023; only 2% show cancer on imaging follow-up). Contrast ultrasound (CEUS) rules out cyst-wall blood flow with 100% negative predictive value and zero kidney risk (Desai Radiographics 2026). Bosniak III (only 10.3% aggressive cells, Tse Radiology 2026) and Bosniak IV go to urology for active watching or partial removal.
- Adrenal (ACR 2021): Nodules under 1.0 cm need no workup. Any nodule measuring 10 HU or less on non-contrast CT or showing fat content on chemical-shift MRI (94% sensitivity and 95% specificity, Platzek 2019) is a benign fat-rich adenoma (0% cancer risk) and needs no follow-up.
- Pancreas (ACR Pancreas White Paper): Simple cysts under 1.5 cm get calm MRI checks every 1 to 2 years (stopping at age 80). Immediate GI referral for endoscopic ultrasound (EUS) is reserved for cysts 3.0 cm or larger, enhancing wall nodules, or main duct widening 7 to 10 mm or more.
- Thyroid (ACR 2015 White Paper, TI-RADS 2017 and Song Thyroid 2024): Across 6,272 patients with CT thyroid spots (Song 2024), cancer was 3.9% overall (0.1% under 1 cm, 0% under 1.5 cm, and 1.8% across CT, ultrasound, and MRI spots in Willems Thyroid 2026). On CT or MRI, without abnormal lymph nodes or focal PET scan uptake (19% to 31% cancer risk), a thyroid spot does not need an ultrasound if it is under 1.0 cm (under age 35) or under 1.5 cm (age 35 and up). On ultrasound, TR1 (0 pts) and TR2 (2 pts, under 2% risk) need zero biopsy and zero follow-up. ACR TI-RADS biopsies only at 2.5 cm for TR3, 1.5 cm for TR4, or 1.0 cm for TR5 (stopping follow-up at 5 years if stable).
Fishtown Medicine
A 90-minute conversation with Dr. Ash. A written plan you can follow.
| Incidental Finding | Zero Further Workup ("Stop" Rule) | Calm Imaging Surveillance | Referral / Tissue Sampling |
|---|---|---|---|
| Solitary Lung Nodule (Fleischner 2017, age >= 35) | < 6 mm (< 100 mm3), low risk (0.88% vs. 0.77% no-nodule risk, SUMMIT 2025); or pure ground-glass < 6 mm. | 6-8 mm: CT at 6-12 mo (± 18-24 mo); < 6 mm high risk: optional 12-mo CT; ground-glass >= 6 mm: 6-12 mo then q2y to 5 yr. | > 8 mm (> 250 mm3): CT at 3 mo, FDG-PET/CT, or biopsy. |
| Liver Lesion (ACG 2024 & ACR 2017, low risk) | Simple cyst (any size), confirmed hemangioma (any size, OCPs ok), confirmed FNH (any size), or smooth < 1 cm spot. | Hepatocellular adenoma in women < 5 cm: stop OCPs/hormones + MRI q6m for 2 yr, then yearly. | Indeterminate >= 1.0-1.5 cm: Multiphasic Gadoxetate MRI or CEUS first; adenoma in men (any size) or >= 5 cm -> surgery. |
| Renal Cyst (Bosniak v2019 & AUA 2021) | Bosniak I (<= 2 mm wall) & Bosniak II (1-3 thin septa or homogeneous >= 70 HU unenhanced CT, > 99.9% benign). | Bosniak IIF (3 mm wall or >= 4 thin septa): CT/MRI at 6 mo, 12 mo, then yearly to 5 yr (2% imaging progression). | Bosniak III / IV: Urology referral for active surveillance (AUA 2021) or partial nephrectomy. |
| Thyroid Nodule (ACR 2015 & TI-RADS 2017) | CT/MRI < 1.0 cm (age < 35) or < 1.5 cm (age >= 35) (0% cancer < 1.5 cm, Song 2024); or ultrasound TR1 / TR2. | Ultrasound follow-up (stop at 5 yr if stable): TR3 >= 1.5 cm (1, 3, 5y), TR4 >= 1.0 cm (1, 2, 3, 5y), TR5 >= 0.5 cm (q1y-5y). | Fine-Needle Biopsy (FNA): TR3 >= 2.5 cm, TR4 >= 1.5 cm, TR5 >= 1.0 cm, or any focal FDG-PET avid nodule (19%-31% risk). |
Guidance from the clinic
Actionable Steps for Informed Imaging
Use these four triggers before or after booking a boutique scan:
- If you have not booked a scan yet -> check your family history and baseline labs first: Start with a genetic and family history review, ApoB, Lp(a), fasting insulin, and standard colon, breast, cervical, and skin screening. Do those before spending $2,000+ on a magnet.
- If your main worry is heart disease or belly fat -> pick CAC/CCTA and DEXA instead of a full-body MRI: Whole-body MRI is a poor tool for heart arteries. A $100 calcium score or $450 standard-read coronary CT angiogram paired with a $100 to $150 DEXA scan gives sharper answers for a fraction of the price.
- If you already have a Prenuvo or Ezra report flagging a cyst or nodule -> apply ACR size cutoffs and non-invasive tie-breakers (CEUS, chemical-shift MRI, or Gadoxetate MRI) before any biopsy: Upload your PDF and DICOM link. Most liver spots under 1.5 cm, Bosniak I and II kidney cysts, adrenal nodules under 1 cm, and thyroid spots under 1.5 cm (age 35+) need zero follow-up.
- If you have a strong multi-cancer family history -> compare clinical MRI-DWI and liquid biopsy first: We help you weigh whether a hospital full-body MRI protocol or a Galleri multi-cancer blood test fits your risk profile best.
Key Takeaways
- Across 18,043 screened adults, whole-body MRI flags findings in 78% to 95% and triggers follow-up in 15% to 32%, while confirming cancer in 1.1% to 1.6%.
- ACR Incidental Findings White Paper rules safely clear liver spots under 1.5 cm, Bosniak I and II kidney cysts, adrenal adenomas under 1 cm (or 10 HU or less), and thyroid spots under 1.5 cm (at age 35+) without extra testing.
- Non-invasive problem-solving scans (Contrast Ultrasound CEUS, Gadoxetate liver MRI, and Chemical-Shift adrenal MRI) resolve ~90% of indeterminate spots without a needle biopsy.
- Targeted scans (CAC, CCTA, DEXA, low-dose lung CT for smokers) and Tier 1 cancer screens come before boutique whole-body scans.
A note on cost: any discount we negotiate on labs and imaging passes straight through to you, with no markup. Our affordable labs and imaging guide covers how the billing works.
Scientific References
- Kwee RM, Kwee TC. "Whole-Body MRI for Preventive Health Screening: A Systematic Review of the Literature." Journal of Magnetic Resonance Imaging. 2019;50(5):1489-1503. PubMed
- Zugni F, Padhani AR, Koh DM, et al. "Whole-Body Magnetic Resonance Imaging (WB-MRI) for Cancer Screening in Asymptomatic Subjects of the General Population: Review and Recommendations." Cancer Imaging. 2020;20(1):34. PubMed
- Ahsan MD, Frontera N, Gurram A, et al. "The Diagnostic Yield of Whole-Body MRI as a Multi-Disease Screening Modality: A Systematic Review and Meta-Analysis." Journal of General Internal Medicine. 2026. PubMed
- Petralia G, Koh DM, Attariwala R, et al. "Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening." Radiology. 2021;299(3):494-507. PubMed
- MacMahon H, Naidich DP, Goo JM, et al. "Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017." Radiology. 2017;284(1):228-243; and Creamer AW, Horst C, Verghese P, et al. (SUMMIT Study). Thorax. 2025;80(7):454-462.
- Frenette C, Mendiratta-Lala M, Salgia R, et al. "ACG Clinical Guideline: Focal Liver Lesions." American Journal of Gastroenterology. 2024;119(7):1235-1271; and Gore RM, Pickhardt PJ, Mortele KJ, et al. (ACR Liver White Paper). Journal of the American College of Radiology. 2017;14(11):1429-1437. PubMed
- Silverman SG, Pedrosa I, Ellis JH, et al. "Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment." Radiology. 2019;292(2):475-488; McGrath TA, Davenport MS, Silverman SG, et al. AJR American Journal of Roentgenology. 2025;224(3):e2432056; and Tse JR, Shen L, Shen J, et al. Radiology. 2026;318(2):e252431.
- Hoang JK, Langer JE, Middleton WD, et al. (ACR Incidental Thyroid Nodules). Journal of the American College of Radiology. 2015;12(2):143-150; Tessler FN, Middleton WD, Grant EG, et al. (ACR TI-RADS). Journal of the American College of Radiology. 2017;14(5):587-595; Song Z, Wu C, Fang J, et al. Thyroid. 2024;34(9):1113-1122; and Willems J, et al. Thyroid. 2026;36(1):56-65.
- Platzek I, Sieron D, Plodeck V, et al. "Chemical Shift Imaging for Evaluation of Adrenal Masses: A Systematic Review and Meta-Analysis." European Radiology. 2019;29(2):806-815. PubMed
- Wu M, Li L, Wang J, et al. "Contrast-Enhanced US for Characterization of Focal Liver Lesions: A Comprehensive Meta-Analysis." European Radiology. 2018;28(5):2077-2088. PubMed
Dr. Ash is a board-certified internal medicine physician specializing in preventive medicine and healthspan optimization at Fishtown Medicine in Philadelphia.
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.





